Pediatric Patients

This review pools available pediatric data showing ustekinumab can induce and maintain remission after anti‑TNF failure, offering a treatment option for children with refractory IBD. Results are most robust for Crohn’s...

Probiotics like Lactobacillus GG are often considered by families of children with Crohn’s disease. If helpful, they could offer a low-risk adjunct that targets the gut microbiome and barrier function. This pilot study...

Finding a pathogenic HMBS variant in a child with extensive ulcerative colitis suggests rare genetic conditions (like acute intermittent porphyria) can appear alongside or mimic IBD and might affect symptoms or...

Noninvasive monitoring matters for children with UC because endoscopy is burdensome. If ultrasound (and simple measures like bowel wall thickness) can reliably detect moderate-to-severe disease, families may avoid some...

Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...

The study shows that more children worldwide are living with early-onset IBD even as mortality has fallen, and it highlights persistent socioeconomic disparities—important for families and clinicians tracking pediatric...

Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...

Cure8 found this source from BMC Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Tests and monitoring. Open the original article for the full details.

This review found that children with atopic dermatitis have a modestly higher risk of later developing IBD (both Crohn’s disease and ulcerative colitis). Awareness of this association may help clinicians and families...

This trial could expand approved treatment options for children with moderate to severe UC by testing the safety, pharmacokinetics, and maintenance dosing of risankizumab in pediatric age groups.

This study describes how IBD presents and early outcomes in children at a tertiary center, noting high rates of inflammation, nutritional problems, and early flares. Findings may help families and clinicians understand...

Endoscopy in this pediatric multicenter series found a high diagnostic yield and confirmed IBD and other treatable conditions; this matters for families and clinicians in resource-limited settings because improving...

Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...

Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.

A successful Phase 3 trial could provide a new treatment option specifically studied in children with moderate‑to‑severe Crohn's disease, addressing a pediatric population often underrepresented in trials.

Colorectal lymphoma in children can mimic IBD flares or cause surgical emergencies; recognizing this can prevent inappropriate escalation of immunosuppression and speed correct diagnosis and treatment.

Patients and families with pediatric UC may be interested because the study tests FMT plus partial enteral nutrition as a potential new treatment approach for children who haven’t responded to standard therapy and as a...

Genetic primary bile acid malabsorption can produce IBD-like symptoms and may be missed in children labeled with Crohn's disease; recognizing PBAM could change testing and management for some patients.

Many people worry that medications taken during pregnancy could affect a child’s long-term health. This large study suggests that prenatal use of acid-suppressive drugs is not clearly linked to a meaningful increase in...

Growth and nutrition are major concerns in children with Crohn’s disease. This study suggests perianal disease and common inflammatory and nutritional markers may help predict which children are at higher risk for...

The study pinpoints a genetic cause (BIRC3 variants) that disrupts a TNF/RIPK1 immune pathway linked to Crohn’s disease, suggesting a targetable mechanism. That could help doctors match patients to treatments and guide...

Diet-based induction options matter for children because EEN can be hard to tolerate. This study finds CDED (with partial enteral nutrition) performs similarly to EEN for inducing remission and mucosal healing in...

People with Crohn’s disease and their families may relate to the caregiving, hospital stays, and the need for community support when managing complex chronic illness. The story highlights practical and emotional burdens...

Cure8 found this source from caledonianrecord.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Crohn's disease, and Vedolizumab. Open the original article for the full details.

This could expand an approved, gut-targeted biologic (vedolizumab/ENTYVIO) to children as young as 2 with UC or Crohn’s disease, addressing a pediatric treatment gap if the FDA approves the sBLA. Families and clinicians...

IBD in children can affect growth, school life, and emotional health, and early recognition reduces risk of complications. Families should know warning signs and that very early‑onset cases may need genetic evaluation...

Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from jnj.com.

Financial support programs can reduce education-related stress for students managing Crohn’s or colitis and recognize the challenges of juggling symptoms and school. If you or a family member with IBD are pursuing...

Fatigue affects a large majority of pediatric IBD patients and is linked to worse quality of life even when disease is in remission, so it’s a common problem families and clinicians will likely encounter. Understanding...

Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Pediatrics and family. The original article is from cureus.com.

Community events like this connect people with IBD to clinical expertise and peer support. Intestinal ultrasound is a monitoring tool many patients may hear more about and could discuss with their care team.

Perianal abscesses or fistulas in children can be an early sign of Crohn's disease. Recognizing which kids are at higher risk helps guide follow-up and testing so diagnosis isn't delayed.

Noninfectious (aseptic) abscesses or persistent lymphadenitis can be an early extraintestinal sign of IBD in children. Recognizing this link can prompt appropriate imaging and endoscopic evaluation that may lead to...

Based on the title and source metadata, this appears to be a patient story related to Community and awareness. The original article is from dispatch.com.

Cure8 found this source from dispatch.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Community and awareness. Open the original article for the full details.

Personal stories show how IBD affects daily life and mental health and point to local fundraising and community support opportunities. The article names a commonly used biologic (Remicade/infliximab) and describes...

Fundraisers like this directly support the Crohn’s & Colitis Foundation, which provides resources and programs that can benefit people with IBD and pediatric gastroenterology patients. It also shows local clinical teams’...

This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...

Human stories can help people with Crohn’s disease feel less alone and learn that effective care can improve school, activities, and daily life. Local health system profiles also point to resources patients might...

Anaemia is common in children with IBD and can affect growth and cognitive development. Knowing how often it occurs, how severe it is, and how often it persists helps families and clinicians prioritize testing and...

Two new Irish-led studies describe non-drug options that could affect how Crohn’s is treated: a dietary regimen for children that may sustain remission, and a surgical technique that may lower post-op relapse and...

This EC approval means ustekinumab (Stelara) is now an authorised treatment option in the EU for certain children and adolescents with moderate–severe Crohn’s disease who have not responded to other treatments.

Regulatory approval means ustekinumab (Stelara) can now be prescribed in the EU for some children with moderate‑to‑severe Crohn’s disease who haven’t responded to other treatments. This expands treatment options for...

A new EC approval makes ustekinumab an approved treatment option for children and adolescents (≥40 kg) with moderate–severe Crohn’s disease, potentially expanding choices for patients who haven’t responded to other...

IBD can present in uncommon ways in children — including as an intraluminal abdominal mass that mimics tumors. Early recognition avoids misdiagnosis and guides appropriate surgical and medical follow-up.

Research that maps neutrophil behavior in children with Crohn’s could reveal biological mechanisms and biomarkers relevant to disease progression or treatment response. Understanding neutrophil roles helps scientists...

Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Adalimumab, and Anti-TNF. Open the original article for the full details.

New treatment studies and biosimilars could affect future options and access to care. The piece also points out growing pediatric Crohn’s care and supports available (like an infusion center).